Oral / Subcutaneous · GLP-1 / GLP-2 dual
PG-102 / RT-114
4 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
4
Active
3
Recruiting
1
Completed
1
Sites
16
Countries
2
Endpoints
43
Composite endpoints
2
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
2
2
1
1
1
1
1
1
1
1
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT06712615Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes | PG-102 / RT-114 Obesity / overweight, Type 2 diabetes | HbA1c 7-10% | Ph 2 | Active, not recruiting | 14 | Oct 2025 | — | |
| NCT06309667A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants. | PG-102 / RT-114 Healthy volunteers, Obesity / overweight | BMI 18-30 | Ph 1 | Completed | 1 | Feb 2025 | 1 | |
| NCT07187856Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus | PG-102 / RT-114, Semaglutide Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 2 | Not yet recruiting | 1 | Sep 2026 | — | |
| NCT06891287An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers. | PG-102 / RT-114 Healthy volunteers, Obesity / overweight | — | Ph 1 | Recruiting | 1 | Dec 2026 | — |